Bösartige Neubildungen der Harnblase stellen häufige Tumoren dar, deren Zunahme in den letzten 20 Jahren unter anderem im Zusammenhang mit der umweltbedingten multifaktoriellen Erhòhung der Karzinogene gesehen wird. Die primäre Behandlung oberflächlicher Harnblasenkarzinome ist die transurethrale Resektion. Die üτ > tz kompletter chirurgischer Entfernung hohe Rezidivhäufigkeit kann mit topisch angewandten Substanzen gesenkt werden. Diesbezüglich haben sich eine Reihe von Zytostatika (z.B. Mitomycin C, Adriblastin, Etoposid) und Immuntherapeutika (z.B. BCG, KLH) als wirksam erwiesen. Unter den Immuntherapeutika scheint Immunocyanin – eine Variante von KLH, einem Protein der kalifornischen Schlüssellochschnecke Megathura crenulata – von großem Interesse zu sein. Aufgrund der bisherigen Studien zeigt sich Immunocyanin in der Rezidivprophylaxe oberflächlicher Harnblasenkarzinome als eine topisch vergleichbar wirksame immunmodulatorische Substanz mit geringer Nebenwir-kungsrate.

Keywords:
Oberflächliches Harnblasenkarzinom, Rezidivprophylaxe, KLH, Immunocyanin, Hämocyanin
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.